Metastatic Renal Cell Carcinoma
Conditions
Keywords
metastatic renal cell carcinoma, molecular classification, ctDNA dynamic monitoring, targeted therapy, targeted therapy combined with immunotherapy
Brief summary
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.
Interventions
Single targeted therapy
DRUGPD-1 inhibitor combined with axitinib
targeted therapy combined with immunotherapy
Sponsors
Ruijin Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
West China Hospital
Xiangya Hospital of Central South University
Fudan University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital of Nantong University
Peking University First Hospital
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Zhejiang University
First Affiliated Hospital of Wenzhou Medical University
Sir Run Run Shaw Hospital
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The General Hospital of Eastern Theater Command
The First Affiliated Hospital with Nanjing Medical University
The First Affiliated Hospital of University of Science and Technology of China
The Second Hospital of Anhui Medical University
Tongji Hospital
The First Affiliated Hospital of Zhengzhou University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Peking Union Medical College Hospital
The First Affiliated Hospital of Shanxi Medical University
Shanxi Provincial Cancer Hospital
Changzhi Medical College
First Affiliated Hospital Xi'an Jiaotong University
Second Affiliated Hospital of Xi'an Jiaotong University
The First Affiliated Hospital of Air Force Medicial University
Tang-Du Hospital
Quanzhou First Hospital
Third Affiliated Hospital, Sun Yat-Sen University
RenJi Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Clinically diagnosed with renal cell carcinoma confirmed by pathology, including clear renal cell carcinoma and type I papillary renal cell carcinoma, type II papillary renal cell carcinoma, chromophobe renal cell carcinoma and renal cell carcinoma with sarcomatoid differentiation, etc * Have distant metastasis * metastatic RCC * Eastern Cooperative Oncology Group 0 to 1 * No obvious abnormality was found in blood routine examination, coagulation and liver and kidney function
Exclusion criteria
* • Previously received systematic treatment * Failure to obtain baseline tumor tissue / blood samples * A history of infection with human immunodeficiency virus, or suffer from other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation, or have a history of organ transplantation * A history of allergy to disease treatment drugs * During lactation or pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | From drug taken until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate | From drug taken until the date of first documented progression, assessed up to 20 months |
Countries
China
Contacts
Primary Contactwei xue
Backup Contactjiwei huang, M.D
Outcome results
None listed